189 related articles for article (PubMed ID: 36493334)
21. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
23. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
24. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Jiang M; Chen W; Hu Y; Chen C; Li H
Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Ribi K; Luo W; Bernhard J; Francis PA; Burstein HJ; Ciruelos E; Bellet M; Pavesi L; Lluch A; Visini M; Parmar V; Tondini C; Kerbrat P; Perelló A; Neven P; Torres R; Lombardi D; Puglisi F; Karlsson P; Ruhstaller T; Colleoni M; Coates AS; Goldhirsch A; Price KN; Gelber RD; Regan MM; Fleming GF
J Clin Oncol; 2016 May; 34(14):1601-10. PubMed ID: 27022111
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
[TBL] [Abstract][Full Text] [Related]
28. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
[TBL] [Abstract][Full Text] [Related]
29. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
[TBL] [Abstract][Full Text] [Related]
31. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China.
Zhong X; Chen P; He P; Wu Y; Suo J; Zhu K; Yan X; Tian T; Yang Q; Luo T
Clin Breast Cancer; 2024 Feb; 24(2):e41-e50. PubMed ID: 37865566
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors plus ovarian function suppression versus tamoxifen plus ovarian function suppression for premenopausal women with early stage breast cancer: a systematic review and meta-analysis.
Meng J; Wang X; Guan Y; Zhang D
Ann Palliat Med; 2020 Jul; 9(4):2294-2302. PubMed ID: 32434371
[TBL] [Abstract][Full Text] [Related]
34. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
35. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
[TBL] [Abstract][Full Text] [Related]
36. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer.
Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
[TBL] [Abstract][Full Text] [Related]
38. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Azim HA; Davidson NE; Ruddy KJ
Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
[TBL] [Abstract][Full Text] [Related]
39. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O
Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092
[TBL] [Abstract][Full Text] [Related]
40. Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Colleoni M; Munzone E
Breast; 2015 Nov; 24 Suppl 2():S11-4. PubMed ID: 26249119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
